[This entry is marked for removal.]

E-Z-EM, Inc. is headquartered in New York and develops, manufactures and markets diagnostic imaging products used by radiologists like the MRI bowel marker Gadolite® Oral Suspension.
In addition to medical diagnostics systems, the company's products include MR-compatible interventional devices, such as biopsy needles. E-Z-EM is also a third-party contract manufacturer of contrast media.
Bracco Diagnostics, Inc. , the US-based subsidiary of Bracco Imaging S.p.A. and part of the Bracco Group, announced in Oct. 2007 that it has entered into a merger agreement to acquire E-Z-EM, Inc. (NASDAQ: EZEM) for a total consideration of about $ 240 million. Upon completion of the procedure and subject to the approval of the regulatory authorities, Bracco Diagnostics Inc. will incorporate E-Z-EM.

An oral suspension of synthetic crystalline aqueous orange-flavored MRI contrast agent to enhance delineation of the bowel. Gadolite contains gadolinium, a lanthanide metal with paramagnetic characteristics. The toxic Gd is bound to become inert, along with water, inside a zeolite crystalline lattice structure. Gadolite gives a bright signal, and provides improved definition of the gastrointestinal tract from adjacent tissues.
Pharmacyclics receives an approvable letter from the FDA for Gadolite® Oral Suspension and in the United Kingdom an European marketing agreement signed with E-Z-Em, Ltd. in Dec. 1996.